Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
KLRS
KLRS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KLRS News
Kalaris Gains Momentum with Promising Initial Results from Neovascular AMD Trial and $50 Million Financing Support
Dec 18 2025
NASDAQ.COM
Kalaris Therapeutics Secures $50 Million in Private Placement Financing
Dec 17 2025
Globenewswire
Kalaris Therapeutics Secures $50 Million in Private Placement Financing
Dec 17 2025
Newsfilter
Kalaris TH103 Shows Significant Visual Improvement in Initial Clinical Trial Data
Dec 17 2025
Newsfilter
Monday's Underperforming Sectors: Biotechnology, Electronic Equipment, and Products
Dec 01 2025
NASDAQ.COM
Kalaris Enhances Leadership by Appointing Matthew Gall, MBA, as CFO
Nov 03 2025
Newsfilter
Kalaris Therapeutics Names Matthew Gall as Chief Financial Officer
Nov 03 2025
NASDAQ.COM
Kalaris Therapeutics Begins Enrollment for Phase 1b/2 Study of TH103 in Patients with Neovascular Age-Related Macular Degeneration
Sep 15 2025
Newsfilter
Kalaris Therapeutics Inc. (KLRS) Receives Upgrade to Buy: Key Information to Consider
Sep 01 2025
NASDAQ.COM
Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Aug 28 2025
Benzinga
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
Jun 05 2025
Globenewswire
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
May 16 2025
Benzinga
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Apr 04 2025
Newsfilter
Show More News
